Loading...
Market
Will 5 African countries adopt Lenacapavir for HIV prevention by 2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from African health ministries or Gilead press releases
Story
Global Leaders Back Lenacapavir, Gilead's HIV Drug with 100% Efficacy in Phase 3 Testing, Single Shot Every Year
Dec 15, 2024, 03:44 PM
Global leaders are uniting to support the development of an injectable medication aimed at eradicating HIV. Gilead Sciences announced plans to initiate Phase 3 testing for Lenacapavir, a drug that could potentially prevent HIV infection with just a single annual injection. This medication has been recognized as a significant scientific advancement, with reports highlighting its remarkable efficacy. A large trial conducted in June involving African adolescent girls and young women demonstrated that the treatment reduced HIV infections to zero, achieving an efficacy rate of 100%. This finding was corroborated by a subsequent trial conducted across multiple regions three months later, reinforcing the drug's potential impact in the fight against HIV/AIDS.
View original story
Similar markets
South Africa • 25%
Uganda • 25%
Both countries • 25%
Neither country • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
South Africa • 25%
Kenya • 25%
Nigeria • 25%
Other • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%